Artiva Biotherapeutics (ARTV) Income Statement (2023 - 2025)
Income Statement report data from Mar 31, 2023 to Dec 31, 2025 for Artiva Biotherapeutics (ARTV).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | ||||||||||||
Total Revenue | -4.80M | 1.37M (-12.18%) | 1.56M (-16.13%) | 1.86M | -2.52M | 1.85M (+172.06%) | 680K (+172.00%) | 250K (-90.97%) | 2.77M (-89.61%) | 27M (+661.71%) | 3.50M | - |
Operating Expenses | ||||||||||||
Research And Development | 17M (-3.63%) | 18M (-1.29%) | 18M (+4.75%) | 17M (+28.00%) | 13M (-1.48%) | 14M (+9.65%) | 12M (+10.48%) | 11M (-56.94%) | 26M (+98.32%) | 13M (+16.07%) | 11M | - |
Selling General And Administrative | 4.94M (-6.08%) | 5.26M (+6.26%) | 4.95M (-3.32%) | 5.12M (+3.43%) | 4.95M (+2.91%) | 4.81M (+24.61%) | 3.86M (+7.52%) | 3.59M (-49.22%) | 7.07M (+154.32%) | 2.78M (-31.53%) | 4.06M | - |
Operating Expenses | 22M (-4.24%) | 23M (+0.39%) | 23M (+2.89%) | 22M (+21.35%) | 18M (-0.38%) | 18M (+13.28%) | 16M (+9.84%) | 15M (-55.33%) | 33M (+108.20%) | 16M (+3.46%) | 15M | - |
Depreciation And Amortization | 770K (+28.33%) | 600K (0.00%) | 600K (-4.76%) | 630K (-1.56%) | 640K (+6.67%) | 600K (0.00%) | 600K (+1.69%) | 590K (-49.57%) | 1.17M (+95.00%) | 600K (+20.00%) | 500K | - |
Operating Income | ||||||||||||
Operating Income | -21.93M (-4.24%) | -22.90M (+0.39%) | -22.81M (+2.89%) | -22.17M (+21.41%) | -18.26M (-0.38%) | -18.33M (+13.22%) | -16.19M (+11.73%) | -14.49M (-51.15%) | -29.66M | 11M | -11.82M | - |
Ebit | -21.93M (-4.24%) | -22.90M (+0.39%) | -22.81M (+2.89%) | -22.17M (+21.41%) | -18.26M (-0.38%) | -18.33M (+13.22%) | -16.19M (+11.73%) | -14.49M (+11.98%) | -12.94M | 11M | -11.82M (-29.31%) | -16.72M |
EBITDA | -21.16M (-5.11%) | -22.30M (+0.41%) | -22.21M (+3.11%) | -21.54M (+22.25%) | -17.62M (-0.62%) | -17.73M (+13.73%) | -15.59M (+12.16%) | -13.90M (+18.10%) | -11.77M | 11M | -11.32M (-32.30%) | -16.72M |
Other Income / Expenses | ||||||||||||
Other Non Operating Income | -10.00K | - | - | - | 160K | -10.00K | 20K (-86.67%) | 150K (-25.00%) | 200K (+300.00%) | 50K (+66.67%) | 30K | - |
Net Income | ||||||||||||
Income Before Tax | - | - | - | - | -65.37M | - | - | - | -28.65M | - | - | - |
Income Tax Expense | - | - | - | - | - | - | - | - | 70K | - | - | - |
Net Income From Continuing Operations | -20.77M (-3.53%) | -21.53M (+1.32%) | -21.25M (+4.63%) | -20.31M (+26.23%) | -16.09M (-7.90%) | -17.47M (-2.07%) | -17.84M (+27.79%) | -13.96M (+16.33%) | -12.00M | 11M | -11.28M (-32.54%) | -16.72M |
Net Income | -20.77M (-3.53%) | -21.53M (+1.32%) | -21.25M (+4.63%) | -20.31M (+26.23%) | -16.09M (-7.90%) | -17.47M (-2.07%) | -17.84M (+27.79%) | -13.96M (+16.33%) | -12.00M | 11M | -11.28M (-32.54%) | -16.72M |
Comprehensive Income Net Of Tax | -83.63M (+290.07%) | -21.44M (+0.89%) | -21.25M (+5.30%) | -20.18M (-69.34%) | -65.81M (+281.51%) | -17.25M (-3.79%) | -17.93M (+27.52%) | -14.06M (-50.51%) | -28.41M | 11M | -11.16M | - |